Eikon Therapeutics, Inc. · NASDAQ:EIKN
Eikon Therapeutics — Q2 2026 Earnings Presentation
34 slides from Eikon Therapeutics's earnings presentation, May 11, 2026
Slide 1: Q2 Company Presentation May 2026
Q2 Company Presentation May 2026 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation,
Slide 3: Advancing breakthrough therapeutics through the purposeful integration of science and engineering
Advancing breakthrough therapeutics through the purposeful integration of science and engineering © 2026 | 3 Innovative Discovery Machine Learning & Advanced Engineering Experienced Leadership Clinical-Stage Pipeline Eikon is a late-stage clinical biopharmaceutical company
Slide 4: Eikon's leadership team delivers proven depth and experience to bring novel therapies to market
Eikon’s leadership team delivers proven depth and experience to bring novel therapies to market Roger Perlmutter CEO & Board Chair Roy D. Baynes CMO Freddie Bowie CFO Barbara Howes CPO Benjamin Thorner CBO & GC Russ Berman CTO Michael Klobuchar COO Executive Team Board of Directors Kenneth C. Frazie
Slide 5: Deep R&D expertise coupled with proprietary technology combine to develop innovative medicines
Deep R&D expertise coupled with proprietary technology combine to develop innovative medicines Eikon key strengths Leadership team that has supervised 100+ new drug approvals In-house clinical development expertise and executional excellence Proprietary technology to pursue difficult or historically
Slide 6: Eikon's pipeline includes multiple indications addressing significant unmet medical needs
1This Phase 2/3 trial is designed to proceed to completion, subject to interim analysis by a data monitoring committee, and to form the basis for registration; 2 Phase 2 safety and efficacy study nearing completion; United States Food and Drug Administration, or FDA, has allowed us to proceed with t
Slide 7: Our oncology drug development strategy – potential assets
Our oncology drug development strategy – potential assets Immuno-responsive cancers requiring enhanced immune stimulation Advanced cancers with DNA repair abnormalities Hormonally responsive cancers Androgen receptor (AR) antagonists (EIK1006) Checkpoint inhibitor foundation + TLR7/8 dual-agonist (E
Slide 8: EIK1001 – TLR7/8 Dual-Agonist
EIK1001 – TLR7/8 Dual-Agonist
Slide 9: EIK1001: TLR7/8 dual-agonist has potential to complement checkpoint inhibition
EIK1001: Eikon’s TLR7/8 dual-agonist has potential to complement checkpoint inhibition TLR7 and TLR8 activate innate and adaptive anti-tumor immunity TLR7/8 dual-agonist activates both innate and adaptive immune responses TLR7 agonism induces an innate immune response through pDCs and NK cells to en
Slide 10: EIK1001 introduces a systemic proinflammatory signal which may complement checkpoint inhibitor regimens
EIK1001 introduces a systemic proinflammatory signal which may complement traditional checkpoint inhibitor-based regimens Dual agonism stimulates innate and adaptive responses Orthogonal mechanism of action to checkpoint inhibitors Cutaneous administration of resiquimod (EIK1001) has been shown to p
Slide 11: EIK1001 development strategy maximizes potential impact across significant indications
EIK1001 development strategy maximizes potential impact across significant indications Currently conducting three clinical trials: NSCLC Phase 2 exploratory/tolerability study of triplet (chemo, EIK1001, pembrolizumab), initiated in Q1 2024 Advanced Melanoma Phase 2/3 registrational trial in combina
Slide 12: NSCLC standard of care established in KEYNOTE studies of pembrolizumab + chemotherapy
NSCLC standard of care established in KEYNOTE studies of pembrolizumab + chemotherapy vs chemotherapy alone Source(s): DOI(s): 10.1056/NEJMoa1810865; 10.1056/NEJMoa1801005; 10.1200/JCO.22.01989; 10.1200/JCO.22.01990 || NEJM ITT population and JCO, all responses from NEJM are reported as based on the
Slide 13: EIK1001-005 study: ORR and DCR results (N=53)
JReview data as of Oct 27, 2025; data is not fully cleaned All (N=53) n % (95% CI) ORR (CR+PR) 32 60%(46%, 74%) DCR (CR+PR+SD) 47 89%(77%, 96%) Responses are based on RECIST 1.1 Target Lesion Best % Change from Baseline Time on Study EIK1001-005 study fully enrolled: Updated data to be presented at
Slide 14: EIK1001 squamous data shows especially encouraging disease control
EIK1001 squamous data shows especially encouraging disease control (data to be updated at ASCO 2026) Squamous (N=17) n % (95% CI) ORR (CR+PR) 12 71% (44%, 90%) DCR (CR+PR+SD) 17 100% (80%, 100%) Subject Best (%) Change from Baseline Target Lesion Best % Change from Baseline JReview data as of Oct 27
Slide 15: EIK1003/EIK1004: PARP1-Selective Inhibitors for Treatment of Malignancy
EIK1003/EIK1004: PARP1-Selective Inhibitors for Treatment of Malignancy
Slide 16: EIK1003: PARP1 selective inhibitor has potential to overcome current limitations
HRRD = Sensitive Selective EIK1003: Eikon’s PARP1 selective inhibitor has potential to overcome current limitations and expand usage setting PARP1 inhibition and subsequent trapped PARP1 leads to DNA double strand breaks In HR competent cells, DSBs are repaired, in HR deficient cells, DNA damage acc
Slide 17: Improved PARP1 selectivity may mitigate liabilities of currently approved agents
Improved PARP1 selectivity may mitigate liabilities of currently approved agents Normal Hematopoiesis Anemia (reduced red blood cells), neutropenia (low neutrophils) and thrombocytopenia (reduction in platelets) are all associated with the use of non-selective PARP inhibitors 1. Smith MR et al Lance
Slide 18: EIK1003: Recent data provides support for improved tolerability versus conventional PARP inhibitors
EIK1003: Recent data provides support for improved tolerability versus conventional PARP inhibitors Phase 1/2 Trial Initial Dose Escalation Fully Enrolled: Monotherapy and combination data (Cohorts 1A & 1C) to be presented at ASCO 2026 EIK1003 Phase 2 randomized dose optimization trial currently dos
Slide 19: EIK1003: Tumor responses observed in Phase 1/2 trial as monotherapy
EIK1003: Tumor responses observed in Phase 1/2 trial as monotherapy. Results from the fully-enrolled dose-escalation trial to be updated at ASCO 2026. Monotherapy Key Endpoints Adverse Event Summary: Total TEAEs: 96.9% Grade 3 AEs: 43.1% SAEs: 23.1% Treatment Related SAEs: 6.2% Leading to Death: 0%
Slide 20: EIK1003 monotherapy provided encouraging preliminary data regarding durability of responses
EIK1003 monotherapy provided encouraging preliminary data regarding durability of responses (data to be updated at ASCO 2026) JReview data as of Oct 27, 2025; data is not fully cleaned Responses are based on RECIST 1.1 Time on Study Subject Time Since Initiation of Treatment (months)
Slide 21: Encouraging tolerability and disease control for EIK1003 in combination with paclitaxel
Encouraging preliminary tolerability and disease control observed for EIK1003 in combination with paclitaxel (data to be updated at ASCO 2026) JReview data as of Oct 27, 2025; data is not fully cleaned; * “Other” subject in the right plot was identified as a breast cancer patient after Oct 27, 2025;
Slide 22: Eikon Technology Provides Novel Scientific Insights and Permits Rapid Lead Optimization
Eikon Technology Provides Novel Scientific Insights and Permits Rapid Lead Optimization
Slide 23: Eikon's approach: designed to accelerate drug discovery
MAKE TEST ANALYZE DESIGN Eikon’s approach: designed to accelerate drug discovery both conceptually, and through advanced technology ROBOTICS & AUTOMATION SYSTEMS BIOLOGY SINGLE MOLECULE TRACKING AI/ML-ENHANCED DATA ANALYSIS
Slide 24: Single molecule tracking captures real-time dynamics of individual proteins at scale
Single molecule tracking captures the real-time dynamics of individual proteins at scale 0.0 2.5 5.0 7.5 10 Fast Slow Diffusion Coefficient (mm2/s) Membranes | DNA | Target Protein © 2026 | 24
Slide 25: WRN trapping and degradation upon inhibition revealed by Eikon SMT
WRN trapping and degradation upon inhibition revealed by Eikon SMT VCP proteasome WRN WRN Findings led to elucidation of key contributors to WRN inhibitor-driven degradation mechanism slow WRN upon inhibition Shift from fast to slower proteins is quantifiable WRN
Slide 26: Discovery platform advanced WRN program (EIK1005) to clinical candidate in under 18 months
Eikon’s discovery platform advanced WRN program (EIK1005) from tool compound to clinical candidate in under 18 months JAN 2023 Tool compounds targeting WRN helicase identified and synthesized JAN 2023 Eikon identifies novel WRN degradation MOA through SMT platform APR 2023 Eikon generates co-crystal
Slide 27: EIK1005: Clinical program initiated based on favorable xenograft results
EIK1005: Clinical program initiated based on favorable results in tumor xenograft studies Phase 1 starting dose established PK data is encouraging Observed to be generally safe and well-tolerated (in small number of subjects) Tumor volume decrease observed at multiple dose levels in preclinical stud
Slide 28: Androgen receptor overview
Androgen receptor overview Androgens drive proliferation of prostate cancer cells Anti-Androgens block proliferation Two resistance variant mechanisms evade current therapies
Slide 29: Machine learning and computational chemistry guide Eikon's AR antagonist designs
AI/ML + Physics-Based Models Docking vs ML Antagonist Deprioritize Prioritize Predicted AR Antagonism pIC50 Predicted AR Agonism pEC50 Predicted AR Antagonism pEC50 Protein-Ligand Docking Score Agonist Explore, Interactions Not Captured by ML Explore, Unfavorable Protein-Ligand Interactions ML Guide
Slide 30: Eikon's AR programs aim to address limitations of current therapies
Eikon’s AR programs aim to address limitations of current therapies EIK1006 (AR clinical candidate) observed to inhibit tumor growth, reduce PSA levels and alter AR gene expression in preclinical models Observed activity across a range of emerging resistant variants EIK1006 declared clinical candida
Slide 31: Conclusion
Conclusion
Slide 32: Meaningful progress expected across all of our development efforts
Meaningful progress expected across all of our development efforts EIK1001 (TLR 7/8) EIK1003 (PARP1) EIK1004 (PARP1) (CNS-penetrant) EIK1005 (WRN) Phase 2 Non-Squamous NSCLC data readout First interim analysis to choose dose for melanoma study Full Phase 2 NSCLC data readout First patient dosed in N
Slide 33: Eikon Therapeutics highlights
Led by world-renowned drug developers Eikon Therapeutics highlights Technology platform, centered around proprietary single-molecule tracking (SMT) Clinical-stage programs have generated early signs of encouraging clinical activity Internally identified and strategically tailored product candidates
Slide 34: . eIkKON
. eIkKON THERAPEUTICS © Copyright, All Rights Reserved Eikon Therapeutics 2026